Skip to main content

Tousignant Jennifer's Form 4 filing

Viridian Therapeutics, Inc. (VRDN) · filed Aug 20, 2026

Accession no.
0001193125-26-359636
Filed
Aug 20, 2026, 8:05 PM ET
Trade date
Aug 19, 2026
Filing delay
1 day
Rule 10b5-1 plan
Not checked

This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $348.2K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Tousignant JenniferCIK 0002010978Officer (Chief Legal Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 19, 2026Common StockSSaleDisposed−4,212$24.50−$103,1940Direct
Aug 19, 2026Common StockMOption exerciseAcquired+10,000$14.41+$144,10010,000Direct
Aug 19, 2026Common StockSSaleDisposed−10,000$24.50−$245,0000Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 19, 2026Common StockMOption exerciseDisposed−10,000$0.00$0114,072Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)